QN-247, formerly referred to as ALAN (Aptamer Linked Anti Nucleolin), is an aptamer-based investigational drug candidate currently under development and evaluation with the potential to treat a variety of different cancer types, including liquid and solid tumors. A key component of this drug candidate, the QN-165 aptamer, has been tested in over 100 cancer patients and is well tolerated with no evidence of severe side effects; with at least 7 patients having long-lasting clinical responses in which their cancers disappeared or shrank substantially. QN-247 binds the aptamer QN-165 to a gold nanoparticle, which gives it increased potency and versatility. Preclinical studies in breast cancer with QN-247 showed significantly enhanced activity compared to QN-165 alone. The broader versatility conferred on QN-165 by linking it to the nanoparticle includes such uses as enhanced radiation therapy, tumor imaging, and the delivery of other anti-cancer compounds directly to tumor cells.
Potential Additional Indications
QN-247RE, formerly referred to as ALAN-RE (Aptamer Linked Anti Nucleolin – Radiation Enhancement), is an aptamer-based investigational drug candidate currently under development and evaluation to be used in combination with radiation therapy to treat virtually any type of cancer. The gold nanoparticle component of this drug candidate enhances radiation therapy by “magnifying” the effects of radiation on the targeted tumor cells. Because of this beneficial effect, lower doses of radiation can be used, resulting in fewer side effects for patients undergoing radiation therapy for their cancers.
QN-247CE, formerly referred to as ALAN-CE (Aptamer Linked Anti Nucleolin – Contrast Enhancement), is an aptamer-based investigational drug candidate currently under development and evaluation to be used in combination with imaging technologies to provide higher resolution images of solid tumors and tumor cells. Special imaging dyes can be attached to the gold nanoparticle compound, which are then easily detected in tumor cells, providing higher resolution images to radiologists and oncologists.
QN-247 Resource Publications
- AS1411 aptamer-modified theranostic liposomes co-encapsulating manganese oxide nano-contrast agent and paclitaxel for MRI and therapy of cancer† 2019 October
- Targeted Gold Nanoparticle–Oligonucleotide Contrast Agents in Combination with a New Local Voxel-Wise MRI Analysis Algorithm for In Vitro Imaging of Triple-Negative Breast Cancer – 2019 May
- AS1411-conjugated gold nanospheres and their potential for breast cancer therapy – 2015 June